Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

DSpace/Manakin Repository

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
 
TransPORTEC consortium
(2022) Nature Communications, volume 13, issue 1, pp. 1 - 10
(Article)
Abstract
B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid structures (TLS). Here, we investigate the role of B-cells and TLS in endometrial cancer (EC). Single cell RNA-sequencing of B-cells shows presence of naïve B-cells, cycling/germinal center B-cells and antibody-secreting cells. Differential gene expression analysis shows ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Endometrial Neoplasms/pathology, Female, Germinal Center/metabolism, Humans, Immunohistochemistry, Neural Cell Adhesion Molecule L1, Tertiary Lymphoid Structures/genetics, General, General Physics and Astronomy, General Chemistry, General Biochemistry,Genetics and Molecular Biology, Research Support, Non-U.S. Gov't, Journal Article
DOI: https://doi.org/10.1038/s41467-022-29040-x
ISSN: 2041-1723
Publisher: Nature Publishing Group
Note: Funding Information: Dr. Horeweg reports outside of the submitted work to have received research grants from the Dutch Cancer Society (KWF-2021-13400, KWF-2021-13404). Dr. Church is funded by a Cancer Research UK Advanced Clinician Scientist Fellowship (C26642/A27963) and reports to be part of the advisory board for MSD. Prof. Nout, Dr. Bosse and Prof. Creutzberg report to have received a grant from the Dutch Cancer Society for the PORTEC-3 trial (KWF 2018-1-11629). Prof. Koelzer reports grants from Promedica Foundation (F-87701-41-01) during the conduct of the study and having served as an invited speaker on behalf of Indica Labs. Dr. de Bruyn reports, outside the submitted work, having received grants from the Dutch Cancer Society (KWF), grants from the European Research Council (ERC), grants from Health Holland, grants from DCPrime, non-financial support from BioNTech, non-financial support from Surflay, non-financial support from MSD, grants and non-financial support from Vicinivax. In addition, dr. de Bruyn has grants and non-financial support from Aduro Biotech, in part relating to a patent for Antibodies targeting CD103 (de Bruyn et al. No. 62/704,258). The remaining authors declare no competing interests. Funding Information: We gratefully acknowledge the PORTEC-3 study group and TransPORTEC consortium for their contribution to the conduct of the PORTEC-3 trial and the establishment of the TransPORTEC biobank. A list of the members of these consortia is provided in the Supplementary Information. The authors would also like to thank Nienke van Rooij, Diana Spierings and Bart Eggen for their support in the acquisition of the single cell RNA sequencing data. This work was supported by the Dutch Cancer Society (project grants: LUMC KWF-2018-1-11629, RUG 2015-7235 and 8232-21648). This work was supported by The Oxford NIHR Comprehensive Biomedical Research Centre (BRC) and WHG core funding from the Wellcome Trust (203141/Z/16/Z). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health. This is an academic-sponsored, investigator-initiated study, the funding bodies had no role in the study design, data collection, analysis or manuscript writing. Funding Information: We gratefully acknowledge the PORTEC-3 study group and TransPORTEC consortium for their contribution to the conduct of the PORTEC-3 trial and the establishment of the TransPORTEC biobank. A list of the members of these consortia is provided in the Supplementary Information. The authors would also like to thank Nienke van Rooij, Diana Spierings and Bart Eggen for their support in the acquisition of the single cell RNA sequencing data. This work was supported by the Dutch Cancer Society (project grants: LUMC KWF-2018-1-11629, RUG 2015-7235 and 8232-21648). This work was supported by The Oxford NIHR Comprehensive Biomedical Research Centre (BRC) and WHG core funding from the Wellcome Trust (203141/Z/16/Z). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health. This is an academic-sponsored, investigator-initiated study, the funding bodies had no role in the study design, data collection, analysis or manuscript writing. Publisher Copyright: © 2022, The Author(s). © 2022. The Author(s).
(Peer reviewed)